This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Book Reviews

The ADHD-Autism Connection: A Step Toward More Accurate Diagnosis and Effective Treatments

Jeffrey J. Globus, MD

Published: June 1, 2002

Article Abstract

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: I read with interest the letter to the editor by Dr. Ahmed and colleagues at the Lilly Research Laboratories in Indianapolis, Indiana, regarding our article1 in the last issue of the journal. I agree with the authors that olanzapine has the best available data for efficacy in bipolar disorder, which is the reason, as they point out, that it has approval from the U.S. Food and Drug Administration(FDA) for the treatment of acute mania. However, the authors are incorrect in stating that there is no clinical trial demonstrating risperidone’s efficacy as a monotherapeutic agent in bipolar disorder.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 4

Quick Links: Autism Spectrum Disorders , Neurodevelopmental


Sign-up to stay
up-to-date today!


Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...